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Summary We evaluated total plasma fatty acid concentrations and percentages, and the fatty acid profiles for the different plasma lipid
fractions and red blood cell lipids, in 17 patients with untreated colorectal cancer and 12 age-matched controls with no malignant diseases,
from the same geographical area. Cancer patients had significantly lower total plasma concentrations of saturated, monounsaturated and
essential fatty acids and their polyunsaturated derivatives than healthy controls; when the values were expressed as relative percentages,
cancer patients had significantly higher proportions of oleic acid and lower levels of linoleic acid than controls. With regard to lipid fractions,
cancer patients had higher proportions of oleic acid in plasma phospholipids, triglycerides and cholesterol esters, and lower percentages of
linoleic acid and its derivatives. On the other hand, ax-linolenic acid was significantly lower in triglycerides from cancer patients and tended to
be lower in phospholipids. Its derivatives also tended to be lower in phospholipids and triglycerides from cancer patients. Ourfindings suggest
that colorectal cancer patients present abnormalities in plasma and red blood cell fatty acid profiles characterized by lower amounts of most
saturated, monounsaturated and essential fatty acids and their polyunsaturated derivatives, especially members of the n-6 series, than their
healthy age-matched counterparts. These changes are probably due to metabolic changes caused by the illness per se but not to malnutrition.
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Colorectal cancer represents the second most common cause of
death from cancer in western countries (MMWR, 1989). Tumour
growth has a considerable impact on the nutritional status of
patients and on the metabolic use of nutrients involved in the
maintenance of structural integrity at the cellular level (Kern and
Norton, 1988). Specific abnormalities in lipid metabolism have
been reported in patients with cancer, e.g. increased fat mobiliza-
tion from adipose tissue, probably due to soluble factors, such as
'lipid-mobilizing factor' (Kitada et al, 1982; Taylor et al, 1992)
and the toxohormone (Masuno et al, 1981); increased oxidation
rate of free fatty acids (Hansell et al, 1986; Douglas et al, 1990);
and hyperlipidaemia due to either decreased lipoprotein lipase
activity (Memon et al, 1992) or enhanced hepatic lipid secretion
(Feingold et al, 1989).
Essential fatty acids and their polyunsaturated derivatives are
involved in many important biological functions. They play a
structural role in cell membranes, influencing their fluidity and
membrane enzyme activities; in addition, a number of fatty acids
(Dihomo-y-linolenic acid, arachidonic acid and eicosapentaenoic
acid) are the precursors of prostaglandins and other eicosanoids
and can thus modulate immune responses (Kinsella, 1990;
Kinsella et al, 1990). Decreased concentrations of essential fatty
acids, linoleic acid and ct-linolenic acid, and their long-chain
polyunsaturated derivatives have been found in plasma and red
blood cells from patients with bladder and gastrointestinal cancer
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(Mosconi et al, 1989; McClinton et al, 1991). The lower levels of
fatty acid derivatives may result from the decreased activity of
fatty acid desaturase enzymes, particularly the delta-6-desaturase,
in tumour cells (Begin et al, 1986). However, in a study ofpatients
with colorectal cancer, Neoptolemos et al (1991) found increased
arachidonic acid and docosahexaenoic acid concentrations in the
gut mucosa. Moreover, Hendricke et al (1994) have reported high
levels of arachidonic acid and prostaglandins ofthe 2 series in the
mucosa of colorectal tumours of patients who underwent surgery
for colorectal cancer. Both studies are consistent with the sugges-
tion of an increased delta-6-fatty acid desaturase activity in these
tumours.
The present study was designed to test the hypothesis that
colorectal cancer patients would exhibit decreased levels ofessen-
tial fatty acids and long-chain polyunsaturated derivatives in
plasma and erythrocytes as a result of either the metabolic effects
of the illness or dietary factors. We investigated the changes in
fatty acids profiles of plasma, plasma lipid fractions and erythro-
cyte membranes in patients with colorectal cancer, and compared
these results with the findings in control subjects with no malig-
nant diseases.
MATERIALS AND METHODS
Subjects
The cancer group consisted of 17 patients (11 men and six
women), with a mean age of 63.1 (range 35-82) years, with
untreated colorectal cancer. The control group comprised 12 indi-
viduals (eight men and four women) with a mean age of 63.3
(range 33-81) years, with no malignant diseases (five abdominal
hernias, three cataracts, two haemorrhoids, one prostate adenoma,
one cholelithiasis), from the same geographical area as the
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patients. All patients were admitted and evaluated by the Surgery
Service of the Santa Ana Hospital (Motril, Granada province,
Spain) as candidates for surgery for colorectal cancer (cancer
group) and for minor surgery (control group). Patients with known
abnormalities in lipid metabolism or with significant cardiac,
hepatic or renal disease were excluded. The sites of the cancer
were rectum (n = 6), rectosigmoid junction (n = 2), right colon
(n = 2), left colon (n = 2), sigmoid colon (n = 3), splenic flexure
(n = 1) and caecum (n = 1). Tumours were classified as Dukes' A
in two patients, Dukes' B in four patients, Dukes' C in nine
patients and Dukes' D in two patients. Two patients also had gall-
bladder stones. All patients gave their informed consent to take
part in the study, which was approved by the ethical committee of
the hospital and performed in accordance with the guidelines in
the Helsinski Declaration.
Anthropometric parameters, triceps skinfold (TSF), arm muscle
circumference (AMC), mid-arm muscle circumference (MAMA),
arm fat area (MAFA) and serum albumin, prealbumin, transferrin
and total protein were determined using standard methods.
Samples
Blood samples were taken from cancer patients and controls after
an overnight fast and were dispensed into EDTA-treated tubes.
Plasma was obtained after centrifugation at 1500g for 15 min, and
aliquots were placed in separate tubes and stored immediately at
-70°C. Red blood cell membranes were obtained according to the
Steck and Kant (1973) method, as modified by Burton et al (1981).
Plasma lipid fractions were extracted with 2:1 (v/v) chloro-
form-methanol using the Folch et al (1957) procedure and were
separated by thin-layer chromatography on Silica Gel G-60 using
the solvent system described by Skipski and Barclay (1969).
Heptanodecanoic acid (Sigma Chemical, St Louis, MO, USA) was
added as an internal standard (20 mg dl-' plasma) to allow plasma
fatty acid concentrations to be determined as absolute values.
Fatty acids were methylated using a transmethylation reaction
according to the Lepage and Roy (1986) method. Fatty acid
methyl esters were separated and quantified by gas-liquid
chromatography in a 5890A Hewlett-Packard chromatograph
(Philadelphia, PA, USA) equipped with a flame ionization detector
Table 1 Nutritional assessment using biochemical and anthropometric
parameters
Parameter Controla Cancer patientsb
Biochemical parameters
Total protein (g I-') 7.1 ±0.2 6.7± 0.1
Albumin (g1-1) 4.5 ± 0.1 4.2 ±0.1
Prealbumin (mg 1-') 26.6 ± 1.9 21.1 ± 1.6
Transferrin (mg 1-') 291 ±13 273 ± 13
Anthropometric parametersc
TSF 126 ±12 118 ±12
AMC 120±4 113±3
MAMA 143±14 111 ±7
MAFA 138±11 126 ±12
Results are expressed as mean ±s.e.m. aNumber of subjects in this group,
12. bNumber of patients in this group, 17. cThese values were expressed in
percentages with respect to the percentile 50 of the healthy population (100%
values). TSF, triceps skinfold; AMC, arm muscle circumference; MAMA, mid-
arm muscle circumference; MAFA, arm fat area.
and a 30-m length x 0.75-mm internal diameter wide-bore column
impregnated with SP-2330 as the stationary phase (Supelco,
Bellefonte, PA, USA). Nitrogen was used as the carrier gas (20 ml
min-') with air and hydrogen for flame ionization. The injection
temperature was set at 250°C for each run and the oven tempera-
ture was initially held at 165°C for 3 min and ramped at 2°C min-'
to 190°C, then ramped at 3-211°C. Detection was performed at
275°C. Peaks were identified by comparing their retention times
with known standards (Sigma). The results were expressed in
absolute units (mg of fatty acid dl-I plasma) and relative values
(percentages).
Plasma antioxidant analyses
Plasma antioxidant capacity was assessed using pig brain
homogenates as a model system according to the following
method as tested by the Department of Lipid Biochemistry,
Institute of Nutrition and Food Technology, INTA, University of
Chile. Basically, 5 g ofbrain tissue were homogenized in 10 ml of
150 mm, pH 7.4 Tris buffer and centrifuged for 10 min at 1500g at
4°C. Afterremoving the pellet, the protein content was determined
in the supernatant using the Bradford et al (1976) method. We
prepared a control sample with a volume ofsupernatantcontaining
1 mg ofprotein and completed to 0.5 ml with 150 mM, pH 7.4 Tris
buffer. Samples were prepared as the control, with the same
volume of supernatant but adding 50gl of plasma up to 0.5 ml
with 150 mm, pH 7.4 Tris buffer. Controls and samples were
prepared as duplicates and incubated at 370C for 30 min. At the
end of the incubation period, the reaction was stopped with 25 tl
of pure trichloroacetic acid under cold. After that, samples and
controls were centrifuged for 25 min at 1500g at 40C. Then,
350 ,ul of the supernatant was removed and added to 750 gl of
0.67% thiobarbituric acid in 5% trichloroacetic acid in a boiling
water bath for 10 min. Thiobarbituric acid-reactive substances
(TBARS) were determined reading the absorbance at 533 nm
against the sample blank.
The plasma antioxidant capacity was expressed as percentage of
inhibition compared with controls and calculated according to the
following formula:
Plasma antioxidant = 100 - absorbance of sample x 100
capacity absorbance ofcontrol
Statistical analysis
Student's t-test for unpaired data was used to compare the results.
Statistical analyses were performed with the PC-90 statistical soft-
ware package (BMDP Statistical Software, Dos Angeles, CA,
USA) (Dixon et al, 1990). Differences were considered significant
atP<0.05.
RESULTS
Nutritional status
Table 1 shows the nutritional assessment in cancer patients and
controls estimated by biochemical and anthropometric parameters,
which were expressed in percentages with respect to the percentile
50 of the healthy standard Spanish population (100% values)
(Alastrue et al, 1982). There were no major differences between
the values in colorectal cancer patients and those in the controls.
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Table 2 Selected total fatty acid concentrations and percentages in plasma of patients with colorectal cancer
Fatty acid mg dl-' Percentage
Controla Cancer patientSb Controla Cancer patientsb
16:0 56.08 ± 2.49 43.08± 1.74* 18.14 ±0.44 18.47± 0.44
18:0 18.83±0.61 14.10±0.73* 6.11 ±0.12 5.99±0.17
18:1 n-9 63.55 ± 3.24 53.49 ± 2.43* 20.54 ± 0.44 22.85 ± 0.46*
18:1n-7 9.65 ± 0.48 5.59 ± 0.21* 3.14 ± 0.15 2.34± 0.10*
18:2n-6 93.40 ± 15.10 64.44 ± 4.67* 30.23 ± 1.08 26.87 ± 0.70*
20:3n-6 4.80 ± 0.28 3.87 ± 0.29* 1.59 ± 0.09 1.63 ± 0.08
20:4n-6 21.31 ± 1.22 18.59 ± 1.31 6.90 ± 0.31 7.94 ± 0.47
18:3n-3 0.97 ± 0.06 0.70 ± 0.05* 0.31 ± 0.01 0.29 ± 0.02
20:5n-3 2.92 ± 0.60 2.31 ±0.52 0.79± 0.21 0.96± 0.19
22:5n-3 2.21 ± 0.20 1.64 ± 0.12* 0.65 ± 0.09 0.70 ± 0.05
22:6n-3 8.95 ± 0.51 7.00± 0.40* 2.91 ± 0.28 3.02± 0.19
Indices
Tot 295.8 ± 13.6 231.3 ± 10.6* - -
Sat 78.3 ± 2.9 59.3 ± 2.4* 25.4 ± 0.4 25.6 ± 0.4
Mono 84.3 ± 4.1 68.5 ± 2.9* 27.3 ± 0.9 29.5 ± 0.7
n-6 121.9 ± 5.7 90.9± 5.6* 39.5± 1.4 37.2 ± 0.8
n-3 14.0 ± 1.2 11.7 ± 1.3 4.7± 0.4 5.0± 0.4
18:2/20:4 4.5 ± 0.2 3.7 ± 0.3 4.5 ± 0.2 3.7 ± 0.3
Results are expressed as mean ± s.e.m. aNumber of subjects in this group, 12. bNumber of patients in this group, 17. *Significant at P<0.05
compared with control group (t-test). Tot, total fatty acids; Sat, total saturated fatty acids; Mono, total monoenoic fatty acids; n-6, total fatty acids
of the n-6 series; n-3, total fatty acids of the n-3 series.
Table 3 Selected fatty acid composition of plasma lipid fractions of patients with colorectal cancer
Fatty acid Phospholipids Triglycerides Cholesterol esters
Controla Cancer patientsb Controla Cancer patientsb Controla Cancer patientsb
16:0 24.92 ± 0.48 27.80 ± 0.36* 21.73 ± 0.75 23.36 ± 0.57 10.92 ± 0.18 12.94± 0.68*
18:0 12.96 ±0.33 13.61 ±0.38 3.13 ± 0.15 3.97± 0.26* 0.90± 0.05 1.26± 0.22
18:1 n-9 9.62 ± 0.35 10.44 ± 0.43 37.92 ± 1.23 44.96 ± 1.23* 20.23 ± 0.68 23.85 ± 0.72*
18:2n-6 18.69 ±0.78 14.90 ±0.71 18.90 ± 1.15 11.25± 0.75* 51.26+ 1.61 40.28+ 1.58*
20:3n-6 2.75 ± 0.16 2.41 ± 0.15 0.53 ± 0.05 0.26± 0.03* 0.95 ± 0.03 0.66± 0.06*
20:4n-6 8.74 ± 0.40 8.54 ± 0.63 1.25 ± 0.10 0.98± 0.14 7.19± 0.35 8.81 ± 0.71
18:3n-3 0.14 ± 0.06 0.08 ± 0.01 0.45 ± 0.04 0.32 ± 0.03* 0.25 ± 0.03 0.26 ± 0.02
20:5n-3 1.24 ± 0.27 0.81 ± 0.14 0.36 ± 0.08 0.22 ± 0.04 1.09 ± 0.30 1.22 ± 0.25
22:5n-3 1.13 ± 0.09 1.08 ± 0.05 0.40 ± 0.06 0.29 ± 0.04 0.41 ± 0.04 0.39 ± 0.06
22:6n-3 4.12 ±0.3 3.61 ± 0.26 0.98 ± 0.20 0.67± 0.12 0.93± 0.12 0.92 ± 0.05
Indices
Sat 42.5±0.5 46.3±O.6* 26.8±0.9 30.0±0.7* 12.4±0.3 15.3±0.8*
Mono 15.8 ±0.6 17.5 ± 0.6 47.5±1.5 52.3± 1.0* 23.0± 1.2 27.2± 0.8*
n-6 31.7± 1.1 27.4 ±0.7* 21.5±1.3 13.3± 1.2* 60.0± 1.5 50.2± 1.6*
n-3 6.7 ± 0.6 5.7 ± 0.3 2.3 ± 0.4 1.9 ± 0.3 2.3 ± 0.4 2.8 ± 0.3
Results are expressed as mean percentages ± s.e.m. aNumber of subjects in this group, 12. bNumber of patients in this group, 17. *Significant
at P<0.05 compared with control group (t-test). ND, not detectable. Sat, total saturated fatty acids; Mono, total monoenoic fatty acids; n-6, total
fatty acids of the n-6 series; n-3, total fatty acids of the n-3 series.
Total plasma fatty acids
Table 2 shows the fatty acid concentrations and percentages in
plasma of colorectal cancer patients and controls. Cancer patients
showed significantly lower plasma concentrations of palmitic
(16:0), stearic (18:0), oleic (18:ln-9), linoleic (18:2n-6) and a-
linolenic (18:3n-3) fatty acids and of the long-chain polyunsatu-
rated derivatives dihomo-y-linolenic (20:3n-6), docosapentaenoic
(22:5n-3) and docosahexaenoic (22:6n-3) acids. This was reflected
in the lower indices for total, saturated, monounsaturated, n-6 and
n-3 fatty acids (Table 2). When the results were expressed as
percentages, cancer patients showed significantly higher levels of
oleic acid and lower levels oflinoleic acid than controls (Table 2).
The linoleic-arachidonic acid (20:4n-6) ratio tended to be lower in
cancer patients (P < 0.10).
Plasma phospholipids
The average value for the total saturated fatty acids level was
significantly higher in cancer patients than in controls (Table 3)
because of the higher concentration of palmitic acid. The
percentage of linoleic acid was significantly lower in cancer
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Table 4 Selected fatty acid composition of erythrocyte phospholipids in
patients with colorectal cancer
Fatty acid Percentage
Controla Cancer patientsb
16:0 17.78 ± 0.20 18.3 ± 0.24
18:0 13.57 ± 0.11 14.17 ± 0.10O*
18:1n-9 12.50 ± 0.26 10.97 ±0.23
18:2n-6 6.95 ± 0.34 7.06 ± 0.38
20:4n-6 13.50 ± 0.40 14.61 ± 0.24
18:3n-3 0.08 ± 0.01 0.05 ± 0.01
22:6n-3 6.34 ± 0.33 6.25 ± 0.20
Indices
Sat 37.3 ± 0.4 37.4 ± 0.2
Mono 18.7 ±0.4 18.0 ±0.3
n-6 25.1 ± 0.8 26.2 ± 0.6
n-3 9.7 ± 0.7 9.6 ± 0.3
Results are expressed as mean percentages ± s.e.m. aNumber of subjects in
this group, 12. bNumber of patients in this group, 17. *Significant at P<0.05
compared with control group (t-test). Sat, total saturated fatty acids; Mono,
total monoenoic fatty acids; n-6, total fatty acids of the n-6 series; n-3, total
fatty acids of the n-3 series.
patients than in controls; total fatty acids of the n-6 series were
also significantly lower in cancer patients. No major differences
were found for monounsaturated and n-3 fatty acids.
Plasma triglycerides
Cancer patients showed increased levels of 18:0 and 18:ln-9
(Table 3). The relative percentages of both essential fatty acids
(18:2n-6 and 18:3n-3) and the long-chain derivative of the n-6
series (20:3n-6) were lower in cancer patients than in controls.
Whereas saturated and monounsaturated indices were significantly
higher in cancer patients, total n-6 was lower. There was no differ-
ence between the two groups in n-3 fatty acids.
Plasma cholesterol esters
The levels ofpalmitic acid and oleic acid were significantly higher
in cancer patients compared with control values (Table 3). The
percentages of 18:2n-6, the most abundant fatty acid in the choles-
terol ester fraction, and its long-chain derivative 20:3n-6 were
significantly lower in cancer patients. Table 3 shows the increased
saturated and monounsaturated fatty acid indices in cancerpatients
and the lower levels of fatty acids of the n-6 series. There was no
difference between the two groups in the n-3 fatty acids.
Erythrocyte phospholipids
Table 4 shows the relative fatty acid composition oftotal phospho-
lipids in red blood cell membranes. No differences were found
between the two groups, except for the higher levels ofstearic acid
in cancer patients.
Plasma antioxidant capacities
No major differences were found between cancer patients and
controls (54.9 ± 1.7 colorectal cancer patients vs 54.2 ± 1.1
controls).
DISCUSSION
The most significant finding of this study was that the concentra-
tions and percentages ofplasma fatty acids differed in patients with
colorectal cancer in comparison with individuals with no malignant
diseases. The patterns we found suggest that cancer patients have
decreased saturated, monounsaturated and polyunsaturated fatty
acids. These results may be due in part to modifications in the
metabolism of fatty acids in cancer patients, and in part to differ-
ences in diet. Malnutrition, usually associated with cancer, does not
seem to be the cause oflowerplasma fatty levels in our study group
as no major differences were observed in anthropometric parame-
ters and plasma albumin, prealbumin, total protein and transferrin
in colorectal cancer patients compared with values for control
patients with no malignant diseases. McDonagh et al (1992) have
suggested that changes in plasma lipoprotein lipid composition
may be due to peroxidation. These authors also found a decrease in
the total fatty acid concentration, which resulted from preferential
peroxidation of polyunsaturated fatty acids in the plasma of
patients with breast cancer and in mouse plasma after treatment
with tumour necrosis factor alpha (TNF-a). This cytokine induces
a respiratory burst in polymorphonuclear leucocytes, which leads
to the production and release of superoxide, which is readily
converted to hydroxyl- and peroxyl-free radicals (Larrick et al,
1987). We determined the total antioxidative capacity of plasma
and we did not find any differences that may support the theory of
Mcdonagh et al (1992). We think that the decrease in the levels of
plasma fatty acids could be mediated by another mechanism,
namely increase in lipoprotein lipase activity (Semb et al, 1987;
Feingold and Grunfeld, 1992). Another possibility is that the
decrease in polyunsaturated fatty acids might be a way for the
tumour cells to escape from the potential cytotoxic action of fatty
acids. There is a number of reports suggesting that stearic oleic and
essential fatty acids play a cytotoxic role in solid tumours (Siegal et
al, 1987; Begin, 1989; Fermor et al, 1992). Recently, it has been
shown that fatty acid synthase and fatty acid synthetic activity in
colorectal neoplasms is increased (Rashid et al, 1997).
In addition to these metabolic alterations, changes in the plasma
fatty acid profile may be due to dietary factors. The diet of cancer
patients may differ from that of controls, and this may lead to
changes in plasma lipids. In our study, cancer and no-cancer
patients came from the same geographical area, and we assume
that the diet was qualitatively similar in both groups, although
evidence suggests that anorexia, taste changes and low caloric
intake may be prevalent in cancer patients (Gallagher and
Tweedle, 1983; Shils, 1994). Thus, it seems likely that both meta-
bolic and dietary factors may induce plasma fatty acid changes in
colorectal cancer patients.
Most studies offatty acid composition express values as relative
percentages of fatty acids. When our values for total fatty acids in
plasma were expressed as percentages and the different plasma
lipid fractions were analysed, colorectal cancer patients had
increased saturated and monounsaturated fatty acids and decreased
polyunsaturated fatty acids, particularly those of n-6 series. Thus,
the decrease in n-6 fatty acids was apparent not only in absolute
values, but also in relative figures for total plasma and plasma lipid
fractions.
Our results are consistent with those of other studies, including
studies of gastrointestinal cancer (Mosconi et al, 1989), bladder
cancer (McClinton et al, 1991), malignant prostatic disease
(Chaudry et al, 1991) and other malignant diseases (Engan et al,
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1995). Mosconi et al (1989) studied malnourished patients with
tumours of the gastrointestinal tract and suggested that the reduc-
tion in linoleic acid correlated with weight loss as a consequence of
maximal depletion of body stores of this fatty acid. In contrast, the
increased level ofoleic acid may be related more to the disease state
than to malnutrition. Moreover, a desaturating factor supposedly
showing delta-9-desaturase activity (which would convert stearic to
oleic acid and thus raise plasma concentrations of this fatty acid)
has been isolated from tissues, serum and urine of cancer patients
(Habib et al, 1987). Alternatively, the increase in oleic acid may be
an indirect consequence ofthe decreased percentages ofpolyunsat-
urated fatty acid. Our cancer patients also showed significantly
lower plasma levels of 18:2n-6, suggesting a lowerdietary intake or
increased metabolic use. The decreased level of linoleic acid
appears to be more probably related to metabolic alterations caused
by the cancer per se rather than to malnutrition, as biochemical and
anthropometric parameters were similar in the groups considered.
The use ofpolyunsaturated fatty acids by proliferating tumour cells
might decrease the pool of these fatty acids, thereby limiting the
incorporation into lipoproteins.
Arachidonic acid is of special relevance in cancer because it is
the precursor of prostaglandins of the 2 series and other important
eicosanoids. Evidence suggests that eicosanoids are involved in
immune suppression and the promotion of metastasis (Bull et al,
1981; Kinsella et al, 1990; Reddy et al, 1991). So, it is established
that the levels of arachidonic acid are raised in colorectal cancer
tissue compared with normal mucosa (Neoptalemos et al, 1986;
Nicholson et al, 1991; Hendrickse et al, 1994). This increase may
be due to increased delta-6-desaturase activity, probably reflecting
the increased availability of substrate for peroxidation (Kinsella et
al, 1990). In spite of the general decrease in total n-6 fatty acids in
our cancer patients the levels of 20:4n-6 in plasma and plasma
lipid fractions were fairly similar to those ofcontrols. This may be
due to partial reversion of delta-6-fatty acid desaturase inhibition
in the liver: excess amounts of the substrate 18:2n-6 inhibit this
enzymatic system (Brenner, 1990), so if 18:2n-6 is decreased in
colorectal cancer patients, the activity of the enzymatic system
may become higher.
With regard to the n-3 series offatty acid, plasma concentrations
of 18:3n-3 and total n-3 derivatives were lower in cancer patients,
although their relative levels remained unchanged in total plasma,
plasma phospholipids and cholesterol esters. This is consistent
with the changes observed for 20:4n-6 and suggests that levels of
long-chain polyunsaturated fatty acids tend to be preserved in
tissues to maintain cell function, even when essential fatty acids
are decreased.
The fatty acid profiles in red blood cell membranes did not
reflect the alterations found in plasma lipids, probably because of
the slower turnover of structural lipids in membranes than in the
plasma compartment (Glatz et al, 1989).
In conclusion, patients with colorectal cancer had considerable
alterations in the fatty acid profiles of plasma lipids. The patterns
we observed suggest that, in these patients, all saturated, monoun-
saturated and essential fatty acids and their polyunsaturated deriva-
tives are decreased. Lower levels of polyunsaturated fatty acids
(particularly those ofthe n-6 series) were also found in the different
plasma lipid fractions. These results suggest that changes in the
metabolism of fatty acids, but not malnutrition, are the cause of
abnormalities in plasma fatty acid levels in patients with colorectal
cancer. However, the mechanisms of these alterations remain to be
determined. Because essential fatty acids and their polyunsaturated
derivatives are involved in many important biological functions,
and because those fatty acids have been reported to play a cytotoxic
effect on tumour cells, ourfindings also suggest the need for studies
to ascertain the potential clinical benefits ofenriching the diet with
essential and long-chain fatty acids.
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